Attachment II - Page 3 
9206-025* 
9209-026 
9209-02r 
9209-028 
9209-029 
9209-030 
9209-031 
9209-032 
9209-033 
9212-034* 
92 12-035* 
9212-036 
9303-037 
(M) Dunbar, Cynthia, National Institutes of Health, Bethesda, Maryland; Retrovirtd-Mediaud Gene Trantjer of Bone Marrow and 
Peripheral Blood Sum Cells During Autologous Bone Marrow Transplantation for Chronic Myelogenous Leukemia. 
RAC Approval 6-2-92/NIH Approval 8-14-92 
Minor Modification: 1-6-94 
(M) Walker, Robert E., National Institutes of Health, Bethesda, Maryland; A Study of the Safety and Survival of the Adoptive Transfer of 
Genetically Marked Syngeneic Lymphocytes in HIV Irfected Identical Twiru. 
RAC Approval: 9-14-92/NIH Approval 9-3-93 
(M) Schuening, Friedrich Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; A Phase I/U 
Study of PDCY321, a rhGM-CSF/rhIL-3 Fusion Protein, for the Mobilization of Peripheral Blood Stem Cells for Autologous Stem Cell 
Transplantation. 
RAC Approval 9-14-92/NIH Approval: 2-5-93 
Minor Modification: 2/2S/94 
(M) Schuening, Friedrich Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; Evaluation of the 
Use cf Recombinant Human G-CSF Stimulated Peripheral Blood Progenitor Cell Supplementation in Autologous Bone Marrow 
Transplaruation in Patients with Lymphoid Maligrumcies. 
RAC Approval: 9-14-92/NIH Approval 2-5-93 
Protocol aosed: 2-25-94 (merged with protocol # 9209-027) 
(M) Schuening, Friedrich G., Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; A Trial of G-CSF 
Stimulated Peripheral Blood Stem Cells for Engraftment in Identical Twiru. 
RAC Approval: 9-14-92/NIH Approval 2-5-93 
(M) Deisscroth, Albert B., University of Texas MD Anderson Cancer Center, Houston, Texas; Use of Retroviral Markers to Idendjy 
Efficacy of Purging artd Origin of Relapse Following Autologous Bone Marrow and Peripheral Blood Cell Traruplantation in Indolent B 
Cell Neoplasms (Follicular Non-Hodgkin 's Lymphoma or Chronic Lymphocytic Leukemia) Patients. 
RAC Approval: 9-14-92/NIH Approval 12-2-93 
Minor Modification: 11-3-93 
Minor Modification: 11-18-93 
(T) Roth. Jack A. The Universitv of Texas MD Anderson Cancer Center. Houston. Texas: Clinical Protocol for Modification of 
Orxcotene arul Tumor Suppressor Gene Expression in Non-Small Cell Lime Cancer. 
RAC Approval 9-15-92/RAC Approval Withdrawn 12-3-93 
(M) Brenner, Malcolm K., St Jude Children’s Research Hospital, Memphis, Tennessee; A Phase H Trial of the Baxter Neuroblastoma 
Bone Marrow Purging System Using Gene Marking to Assess Efficacy. 
RAC Approval: 9-15-92/NlH Approval 2-5-93 
(T) Lotze, Michael T. and Rubin, Joshua T^ University of Pittsburgh, Pittsburgh, Pennsylvania; Gene Therapy of Cancer: A Pilot Study 
of IL-4 Gene Modified Atuitumor Vaccines. 
RAC Approval: 9-15-92/NIH Approval: 2-5-93 
(T) Crystal Ronald G., National Institutes of Health, Bethesda, Maryland; A Phase I Study, in Cystic Fibrosis Patients, of the Safety, 
Toxicity, and Biological Efficacy of a Single Administration of a Replication Deficient, Recombirumt Adenovirus Carrying the cDNA of 
the Normal Human Cystic Fibrosis Trarumembrane Conductance Regulator Gene in the Lung. 
RAC Approval: 12-3-92/NIH Approval: 4-16-93 
Minor Modification: 5-17-93 
Minor Modification: 10-8-93 
Minor Modification: 11-29-93 
Minor Modification: 2-4-94 
(T) Wilson, James M., University of Pennsylvania, Philadelphia, Pennsylvania; Gene Therapy of Cystic Fibrosis Lung Diseases Using El 
Deleted Adenoviruses: A Phase I Trial. 
RAC Approval: 12-3-92/NIH Approval: 8-26-93 
Minor Modification: 8-17-93 
(M) Welsh, Michael J., Howard Hughes Medical Institute, Iowa Qty, Iowa, and Smith, Alan E., Genzyme Corporation, Framingham, 
Massachusetts; Cystic Fibrosis Gene Therapy Using an Adenovirus Vector: In Vivo Safety and Efficacy in Nasal Epithelium. 
RAC Approval: 12-4-92/NIH Approval: 4-16-93 
Minor Modification: 10-18-93 
(T) Culver, Kenneth W., Iowa Methodist Medical Center, Dcs Moines, Iowa, and Van Gilder, John C; University of Iowa, Iowa City, 
Iowa; Gene Therapy for the Treatment of Malignant Brain Tumors with In Vivo Tumor Transduction with the Herpes Simplex Thymidine 
Kinase Gene /Ganciclovir System. 
RAC Approval: 3-1-93/NIH Approval: 4-16-93 
[ 74 ] 
Recombinant DNA Research, Volume 19 
